Arcutis Biotherapeutics, Inc. ARQT Other program costs — R&D

Other product segments

Similar metrics at other companies

DNTHOther Costs — Research And Development Expense

$1.49M+25.5%

PRAXOther early stage assets — Program-specific expenses

$3.24M+193%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

BCRXOther non-program specific and indirect costs — Research and Development Expense (Excluding Acquired in Process Cost)

$7.42M+13.3%

ROIVOther development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$13.43M-3.9%

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s other program costs — R&D?

Arcutis Biotherapeutics, Inc. (ARQT) reported other program costs — R&D of $95K in Q1 2026.

What does other program costs — R&D mean?

This metric represents the aggregate research and development expenditures allocated to secondary or early-stage therapeutic programs outside of the company's primary lead product candidates. It captures the investment intensity in the broader clinical pipeline and the exploration of new dermatological indications. Monitoring these costs provides insight into the company's long-term innovation strategy and the capital commitment required to diversify its portfolio beyond flagship assets.